Revisiting immune checkpoint inhibitors: new strategies to enhance efficacy and reduce toxicity

Dianying Zhang^#¹, Jingjing Zhao^#^{2

3}, Yujing Zhang⁴, Hongfei Jiang⁵, Dan Liu¹

Affiliations

¹ Medical Education Department, Guangdong Provincial People's Hospital, Zhuhai Hospital (Jinwan Central Hospital of Zhuhai), Zhuhai, China.
² Sleep Medicine Center, Huai'an No.3 People's Hospital, Huai'an, China.
³ Huaian Second Clinical College of Xuzhou Medical University, Huaian, China.
⁴ The Affiliated Cardiovascular Hospital of Qingdao University, Qingdao University, Qingdao, Shandong, China.
⁵ The Affiliated Hospital of Qingdao University, Qingdao University, Qingdao, Shandong, China.

^# Contributed equally.

PMID: 39720720
PMCID: PMC11666542
DOI: 10.3389/fimmu.2024.1490129

Revisiting immune checkpoint inhibitors: new strategies to enhance efficacy and reduce toxicity

Dianying Zhang et al. Front Immunol. 2024.

. 2024 Dec 10:15:1490129.

doi: 10.3389/fimmu.2024.1490129. eCollection 2024.

Authors

Dianying Zhang^#¹, Jingjing Zhao^#^{2

3}, Yujing Zhang⁴, Hongfei Jiang⁵, Dan Liu¹

Affiliations

¹ Medical Education Department, Guangdong Provincial People's Hospital, Zhuhai Hospital (Jinwan Central Hospital of Zhuhai), Zhuhai, China.
² Sleep Medicine Center, Huai'an No.3 People's Hospital, Huai'an, China.
³ Huaian Second Clinical College of Xuzhou Medical University, Huaian, China.
⁴ The Affiliated Cardiovascular Hospital of Qingdao University, Qingdao University, Qingdao, Shandong, China.
⁵ The Affiliated Hospital of Qingdao University, Qingdao University, Qingdao, Shandong, China.

^# Contributed equally.

PMID: 39720720
PMCID: PMC11666542
DOI: 10.3389/fimmu.2024.1490129

No abstract available

Keywords: biomarker-guided therapy; cancer therapy; combination therapies; immune checkpoint inhibitors; immune-related adverse events (irAEs).

PubMed Disclaimer

Conflict of interest statement

The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

Cited by

Resistance in Lung Cancer Immunotherapy and How to Overcome It: Insights from the Genetics Perspective and Combination Therapies Approach.
Zieliński P, Stępień M, Chowaniec H, Kalyta K, Czerniak J, Borowczyk M, Dwojak E, Mroczek M, Dworacki G, Ślubowska A, Markiewicz H, Ałtyn R, Dobosz P. Zieliński P, et al. Cells. 2025 Apr 12;14(8):587. doi: 10.3390/cells14080587. Cells. 2025. PMID: 40277912 Free PMC article. Review.
Combining immune checkpoints with TNFSF agonists: a new horizon for cancer and autoimmune therapies.
Sun L, Li C, Gao T, Liu Z, Hou Y, Han W. Sun L, et al. Front Immunol. 2025 Mar 17;16:1557176. doi: 10.3389/fimmu.2025.1557176. eCollection 2025. Front Immunol. 2025. PMID: 40165967 Free PMC article. No abstract available.
Unveiling the future of cancer stem cell therapy: a narrative exploration of emerging innovations.
Obisi JN, Abimbola ANJ, Babaleye OA, Atidoglo PK, Usin SG, Nwanaforo EO, Patrick-Inezi FS, Fasogbon IV, Chimezie J, Dare CA, Kuti OO, Uti DE, Omeoga HC. Obisi JN, et al. Discov Oncol. 2025 Mar 22;16(1):373. doi: 10.1007/s12672-025-02102-4. Discov Oncol. 2025. PMID: 40120008 Free PMC article. Review.
Exploring the predictive "psycho-biomarkers" for checkpoint immunotherapy in cancer.
Zuo Q, Chen J, Xiao X, Dai Y, Chen L, Liang Y, Wu Y, Huang J, Cui R, Xu R, Chen Q. Zuo Q, et al. Front Immunol. 2025 Jul 21;16:1590670. doi: 10.3389/fimmu.2025.1590670. eCollection 2025. Front Immunol. 2025. PMID: 40761787 Free PMC article.
Real-world safety of carboplatin in non-small cell lung cancer: a retrospective signal detection and subgroup analysis based on the FAERS database.
Wang L, Yang K, Zhao H, Lv P, Cai C, Wang Z, Wang B. Wang L, et al. Front Med (Lausanne). 2025 Jun 16;12:1590738. doi: 10.3389/fmed.2025.1590738. eCollection 2025. Front Med (Lausanne). 2025. PMID: 40589971 Free PMC article.

See all "Cited by" articles

References

1. Qian X, Hu W, Yan J. Nano-Chemotherapy synergize with immune checkpoint inhibitor- A better option? Front Immunol. (2022) 13:963533. - PMC - PubMed
1. Liu Z, Zhu Y, Xie H, Zou Z. Immune-mediated hepatitis induced by immune checkpoint inhibitors: Current updates and future perspectives. Front Pharmacol. (2023) 13:1077468. doi: 10.3389/fphar.2022.1077468 - DOI - PMC - PubMed
1. Xie Q, Zhang P, Wang Y, Mei W, Zeng C. Overcoming resistance to immune checkpoint inhibitors in hepatocellular carcinoma: Challenges and opportunities. Front Oncol. (2022) 12:958720. doi: 10.3389/fonc.2022.958720 - DOI - PMC - PubMed
1. Papouin B, Mussini C, De Martin E, Guettier C. Effets secondaires digestifs et hépatiques des inhibiteurs du checkpoint immunitaire (Immune checkpoint inhibitors: anti-CTLA-4 et anti-PD-1/PD-L1): aspects anatomocliniques. Annales Pathologie. (2018) 38:338–51. doi: 10.1016/j.annpat.2018.07.005 - DOI - PubMed
1. Kato K, Mizuno T, Koseki T, Ito Y, Takahashi K, Tsuboi N, et al. . Frequency of immune checkpoint inhibitor-induced vasculitides: an observational study using data from the Japanese adverse drug event report database. Front Pharmacol. (2022) 13:803706. doi: 10.3389/fphar.2022.803706 - DOI - PMC - PubMed

LinkOut - more resources

Full Text Sources
- Frontiers Media SA
- PubMed Central

Save citation to file

Email citation

Add to Collections

Add to My Bibliography

Your saved search

Create a file for external citation management software

Your RSS Feed

Revisiting immune checkpoint inhibitors: new strategies to enhance efficacy and reduce toxicity

Affiliations

Revisiting immune checkpoint inhibitors: new strategies to enhance efficacy and reduce toxicity

Authors

Affiliations

Conflict of interest statement

Similar articles

Cited by

References

LinkOut - more resources

Full Text Sources